[Photosensitization with DTIC therapy in metastatic malignant melanoma].
Photoreactions developed in five of 43 patients being treated for 30 months with repeat doses of DTIC because of metastasing malignant melanoma. An increase in light sensitivity in the UVA and UVB range can be demonstrated by light-testing in the affected patients but not in controls. It shows a decrease with the metabolism of DTIC. The increase in light sensitivity serves as an additional argument to avoid light exposure during and after DTIC injections.
D000368:Aged; D003606:Dacarbazine / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010787:Photosensitivity Disorders / Q000139:chemically induced*; D012878:Skin Neoplasms / Q000188:drug therapy*
D003606:Dacarbazine
Lichtsensibilisierung unter DTIC-Therapie beim metastasierenden malignen Melanom.